With state-of-the-art facilities across Europe, Polpharma Biologics is at the forefront of the next wave in biopharma, leveraging our knowledge, capabilities and footprint to develop innovative solutions for the industry.
Polpharma Biologics Utrecht B.V.
Discovery, Optimization and Cell Line Development
Located in the Utrecht Science Park, a hub for education, research, entrepreneurship and healthcare. The state-of-the-art facility focuses on the development of production cell lines for monoclonal antibodies (mAbs) and other proteins (including laboratory scale processes), as well as the generation of New Biological Entities (NBEs).
Management Board: Jonathan Robinson, Louis Boon, Emile Van Corven
Chamber of Commerce: 58858466
Polpharma Biologics S.A.
Development and GMP Production of Drug Substance and Drug Product
Located at the heart of one of the most bustling biotechnology, IT and energetics hubs in Poland, our 7,500 square meter R&D and production facility at the Gdansk Science and Technology Park is one of the most modern biotechnology centers in Europe. In Gdansk, we provide process development and GMP production of clinical and medium-scale commercial materials, supported by QC, QA and project management functions. Customized formulations for drug product can also be developed in-house and subsequently tested for stability according to ICH standards. All processes, including fill & finish, can be scaled up and internally transferred to mammalian and microbial GMP-certified production facilities or to external partners. The facility utilizes scale-down models, as well as high-throughput mini and regular bioreactor systems for parallel screening.
Management Board: Jan Krzeweinski, Adriana Kiedzierska-Mencfeld
Polpharma Biologics S.A. with its registered office in Gdańsk, ul. Trzy Lipy 3, 80-172 Gdańsk, entered into the Register of Entrepreneurs maintained by District Court Gdańsk-North in Gdańsk, VII Commercial Division of the National Court Register, under number: 0000763945, holder of a VAT UE identification number: PL 957-11-12-470, share capital of 120 000 000 PLN (paid in full).
Polpharma Biologics Warsaw Sp. Z o.o.
Warsaw, Poland (Operational in 2020)*
Large-Scale Modular Drug Substance and Drug Product Plant
To serve the growing global demand for biopharmaceuticals, a new commercial-scale GMP production facility for drug substance and aseptic fill & finish of drug product is being built in Duchnice, near Warsaw.
Management Board: Frank Ternes, Frederic Papp, Igor Kostyszyn, Wojciech Kowalski
Polpharma Biologics Warsaw Sp. z o.o. with its registered seat in Ożarów Mazowiecki (05-850), Spółdzielcza 4, Duchnice, entered into Commercial Register maintained by District Court for capital city of Warsaw, its XIV Commercial Division of the National Court Register, under number: 0000498732, holder of a VAT UE identification number: PL 1182096979, statistical ID number: 147109384, share capital of 109.835.000 PLN (paid in full).
Contact Polpharma Biologics
For more information on one of our specific facilities or to discuss an upcoming project, contact Polpharma Biologics using the form below.